Navigation Links
OrbusNeich Files Patent Infringement Lawsuit Against Boston Scientific
Date:3/16/2009

FT. LAUDERDALE, Fla. and HONG KONG, March 16 /PRNewswire/ -- OrbusNeich Medical, Inc. ("Orbus" or the "Company"), a designer, developer, manufacturer and marketer of innovative medical devices for the treatment of vascular diseases, today announced that it has filed a lawsuit against Boston Scientific Corporation ("BSC"). The lawsuit, filed in the United States District Court for the Eastern District of Virginia, asserts claims against BSC for patent infringement, breach of contract and for misappropriation of trade secrets. The suit seeks unspecified monetary damages and injunctive relief in connection with its claims.

Orbus is the owner by assignment of all right, title, and interest in U.S. Patent No. 7,329,277 entitled "Stent Having Helical Elements" and U.S. Patent No. 6,821,292 entitled "Crimpable Intraluminal Endoprosthesis Having Helical Elements." In its complaint Orbus alleges, among other things, that BSC has infringed these two Orbus patents relating to its proprietary luminal stent technology. Specifically the complaint alleges:

  • In July of 2000, the Company entered into a Confidential Disclosure Agreement (the "CDA") with BSC in advance of discussions related to a potential business relationship;
  • In connection with these discussions, Orbus provided BSC with a variety of proprietary stent samples and design details, including improved designs present in Orbus' patent application filed in December of 2000, which BSC tested, disassembled and destroyed;
  • Orbus filed provisional patents on certain elements of its design on December 11, 2000 and February 9, 2001. The final associated patents were lawfully issued on February 12, 2008 and November 23, 2004, respectively;
  • BSC filed a patent application with new stent design drawings that were not included in any of the provisional applications over which this new application claimed priority;
  • After BSC commercialized the Liberte stent, Orbus became aware of the theft of its designs by BSC; and
  • BSC has been manufacturing and selling its line of Liberte stent products without consideration to Orbus, the original designer of major aspects of the Liberte product architecture, itself.

"OrbusNeich has made significant investments of both funds and resources to develop this innovative technology that is a considerable improvement upon existing cardiovascular devices," said Al Novak, President and Chief Executive Officer. "The protection of these technologies is of the utmost importance to OrbusNeich, and the many talented people who worked to develop them. OrbusNeich has an obligation to its investors, employees and its physician customers and their patients to protect that property from those who seek to infringe upon its rights. We do not anticipate that this process will have an impact on our employees, customers or vendors."

Additional information about background, products, associated patents and the charges raised, please view the Company's Complaint as submitted to the United States District Court for the Eastern District of Virginia. Copies of the Complaint can be obtained through the Court's electronic filing system at www.vaeb.uscourts.gov.

About OrbusNeich

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Products in the company's product portfolio are stents, balloons and guiding catheters marketed under the names of Genous(TM) Bio-engineered R stent(TM), Blazer(TM), R stent, Scoreflex(TM), Sapphire(TM), Sapphire(TM) NC, Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, FL; Hoevelaken, The Netherlands; Tokyo, Japan; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit www.orbusneich.com.

    Media Contacts:

    Dan Katcher / Ed Trissel
    Joele Frank, Wilkinson Brimmer Katcher
    +1 212-355-4449 (office)
    dkatcher@joelefrank.com
    etrissel@joelefrank.com


'/>"/>
SOURCE OrbusNeich Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. OrbusNeich Receives CE Mark Approval for Scoreflex(TM) Coronary Dilatation Catheter
2. OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan
3. Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
4. OrbusNeich Receives CE Mark Approval for Sapphire(TM) 1.25MM PTCA Dilatation Catheter
5. 5,000 Patients Treated With OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Now Enrolled in Real-Life Use Global Registry
6. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
7. Why Blood and Bone Marrow Donors Are So Important: Extreme Makeover: Home Edition Profiles Blood Drive Honoree Lizzie Bell
8. Santa Monica Media Corporation Files Extension Proxy With SEC to Complete Transaction
9. Unemployment Rises, Profiles International Reveals Whos Hiring
10. Cordex Pharma Files ATPace Formulation Patent
11. United States Files Suit Against Missouri-Based Pharmaceutical to Block Manufacturing and Shipping of Unapproved Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... 2016 , ... PharmMD CEO Robert Yeager announced ... on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will include ... data breaches for the Part D Star Rating improvement and Medication Therapy Management ...
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
(Date:2/11/2016)... ... , ... The annual list showcases the 20 Most Promising SharePoint Solution Providers ... and commitment to the SharePoint ecosystem. A panel of experts and members of CIOReview’s ... recognize and promote technology entrepreneurship. , The survey was made at the end ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... ergoFET force gauges used in physical therapy, occupational therapy and sports medicine clinics, ... resistance cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. ...
(Date:2/11/2016)... ... February 11, 2016 , ... Research led by Providence Health ... common cancer screenings, especially among women. Cancer screenings are often the best way ... The study,“What Does Medicaid Expansion Mean for Cancer Screening and Prevention: Results from ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016 North America , ... MarketsandMarkets, The global market is expected to reach USD 20,190.1 Million ... CAGR of 10.2%. --> North America , ... by MarketsandMarkets, The global market is expected to reach USD 20,190.1 ... a CAGR of 10.2%. --> According to a new ...
(Date:2/10/2016)... SINGAPORE , Feb. 11, 2016  QT Vascular ... "QT Vascular", and together with its subsidiaries, the ... its ongoing litigation with AngioScore, Inc. ("ÄngioScore") (now ... the United States ... (the "Federal Circuit") reversed an earlier district court ...
(Date:2/10/2016)... PITTSBURGH , 10 februari ... och detta pressmeddelande får inte distribueras, vare ... och inga anmälningssedlar kommer att accepteras från ... land där Erbjudandet, distribution av detta pressmeddelande ... strida mot tillämpliga lagar eller regler eller ...
Breaking Medicine Technology: